Report cover image

Chronic Idiopathic Constipation Therapeutic Market by Drug Class (Bulk-Forming Agents, Emollients, Laxatives), Route of Administration (Oral, Parenteral), Distribution Channel - Global Forecast 2024-2030

Publisher 360iResearch
Published Jan 15, 2024
Length 183 Pages
SKU # IRE18437141

Description

Chronic Idiopathic Constipation Therapeutic Market by Drug Class (Bulk-Forming Agents, Emollients, Laxatives), Route of Administration (Oral, Parenteral), Distribution Channel - Global Forecast 2024-2030


The Chronic Idiopathic Constipation Therapeutic Market size was estimated at USD 573.25 million in 2023 and expected to reach USD 619.07 million in 2024, at a CAGR 8.08% to reach USD 987.96 million by 2030.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Chronic Idiopathic Constipation Therapeutic Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Chronic Idiopathic Constipation Therapeutic Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Chronic Idiopathic Constipation Therapeutic Market, highlighting leading vendors and their innovative profiles. These include Abbvie Inc., Albireo Pharma, Inc., Astellas Pharma Inc., Bayer AG, Chugai Pharmaceuticals Co. Ltd., Ferring B.V., GlaxoSmithKline Plc, Johnson & Johnson Services, Inc., Lantheus Holdings, Mallinckrodt Pharmaceuticals, Pfizer, Inc., Salix Pharmaceuticals, Inc. by Bausch Health, Sanofi S.A., and Takeda Pharmaceutical Company.

Market Segmentation & Coverage


This research report categorizes the Chronic Idiopathic Constipation Therapeutic Market to forecast the revenues and analyze trends in each of the following sub-markets:

Drug Class
Bulk-Forming Agents
Emollients
Laxatives
Osmotic Agents
Route of Administration
Oral
Parenteral
Distribution Channel
Hospital Pharmacies
Online Pharmacies
Retail Pharmacies
Region
Americas
Argentina

Brazil

Canada

Mexico

United States
California

Florida

Illinois

New York

Ohio

Pennsylvania

Texas
Asia-Pacific
Australia

China

India

Indonesia

Japan

Malaysia

Philippines

Singapore

South Korea

Taiwan

Thailand

Vietnam
Europe, Middle East & Africa
Denmark

Egypt

Finland

France

Germany

Israel

Italy

Netherlands

Nigeria

Norway

Poland

Qatar

Russia

Saudi Arabia

South Africa

Spain

Sweden

Switzerland

Turkey

United Arab Emirates

United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.
2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Chronic Idiopathic Constipation Therapeutic Market?
2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Chronic Idiopathic Constipation Therapeutic Market?
3. What are the technology trends and regulatory frameworks in the Chronic Idiopathic Constipation Therapeutic Market?
4. What is the market share of the leading vendors in the Chronic Idiopathic Constipation Therapeutic Market?
5. Which modes and strategic moves are suitable for entering the Chronic Idiopathic Constipation Therapeutic Market?

Note: PDF & Excel + Online Access - 1 Year

Table of Contents

183 Pages
1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Chronic Idiopathic Constipation Therapeutic Market, by Region
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Change in lifestyle and dietary
5.1.1.2. Higher utilization of OTC drugs by patients
5.1.1.3. Rise in healthcare expenditure across the world
5.1.2. Restraints
5.1.2.1. Reduced awareness and diagnosis of chronic idiopathic constipation
5.1.3. Opportunities
5.1.3.1. Progress in drug delivery mechanisms
5.1.3.2. Increase in geriatric population globally
5.1.4. Challenges
5.1.4.1. Probable side effects and allergic reactions
5.2. Market Segmentation Analysis
5.3. Market Trend Analysis
5.4. Cumulative Impact of High Inflation
5.5. Porter’s Five Forces Analysis
5.5.1. Threat of New Entrants
5.5.2. Threat of Substitutes
5.5.3. Bargaining Power of Customers
5.5.4. Bargaining Power of Suppliers
5.5.5. Industry Rivalry
5.6. Value Chain & Critical Path Analysis
5.7. Regulatory Framework
6. Chronic Idiopathic Constipation Therapeutic Market, by Drug Class
6.1. Introduction
6.2. Bulk-Forming Agents
6.3. Emollients
6.4. Laxatives
6.5. Osmotic Agents
7. Chronic Idiopathic Constipation Therapeutic Market, by Route of Administration
7.1. Introduction
7.2. Oral
7.3. Parenteral
8. Chronic Idiopathic Constipation Therapeutic Market, by Distribution Channel
8.1. Introduction
8.2. Hospital Pharmacies
8.3. Online Pharmacies
8.4. Retail Pharmacies
9. Americas Chronic Idiopathic Constipation Therapeutic Market
9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States
10. Asia-Pacific Chronic Idiopathic Constipation Therapeutic Market
10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.10. South Korea
10.11. Taiwan
10.12. Thailand
10.13. Vietnam
11. Europe, Middle East & Africa Chronic Idiopathic Constipation Therapeutic Market
11.1. Introduction
11.2. Denmark
11.3. Egypt
11.4. Finland
11.5. France
11.6. Germany
11.7. Israel
11.8. Italy
11.9. Netherlands
11.10. Nigeria
11.11. Norway
11.12. Poland
11.13. Qatar
11.14. Russia
11.15. Saudi Arabia
11.16. South Africa
11.17. Spain
11.18. Sweden
11.19. Switzerland
11.20. Turkey
11.21. United Arab Emirates
11.22. United Kingdom
12. Competitive Landscape
12.1. FPNV Positioning Matrix
12.2. Market Share Analysis, By Key Player
12.3. Competitive Scenario Analysis, By Key Player
13. Competitive Portfolio
13.1. Key Company Profiles
13.1.1. Abbvie Inc.
13.1.2. Albireo Pharma, Inc.
13.1.3. Astellas Pharma Inc.
13.1.4. Bayer AG
13.1.5. Chugai Pharmaceuticals Co. Ltd.
13.1.6. Ferring B.V.
13.1.7. GlaxoSmithKline Plc
13.1.8. Johnson & Johnson Services, Inc.
13.1.9. Lantheus Holdings
13.1.10. Mallinckrodt Pharmaceuticals
13.1.11. Pfizer, Inc.
13.1.12. Salix Pharmaceuticals, Inc. by Bausch Health
13.1.13. Sanofi S.A.
13.1.14. Takeda Pharmaceutical Company
13.2. Key Product Portfolio
14. Appendix
14.1. Discussion Guide
14.2. License & Pricing
FIGURE 1. CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET RESEARCH PROCESS
FIGURE 2. CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, 2023 VS 2030
FIGURE 3. CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY REGION, 2023 VS 2030 (%)
FIGURE 5. CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET DYNAMICS
FIGURE 7. CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DRUG CLASS, 2023 VS 2030 (%)
FIGURE 8. CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DRUG CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 9. CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
FIGURE 10. CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 11. CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
FIGURE 12. CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 13. AMERICAS CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 14. AMERICAS CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 15. UNITED STATES CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 16. UNITED STATES CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 17. ASIA-PACIFIC CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 18. ASIA-PACIFIC CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 21. CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET, FPNV POSITIONING MATRIX, 2023
FIGURE 22. CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SHARE, BY KEY PLAYER, 2023

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us